Residency · Residency · Chronic Pain Management

Cancer Pain Assessment and WHO Analgesic Ladder

Introduction

Pain affects 66-90% of patients with advanced cancer and remains undertreated in roughly 30-50% of cases worldwide. Cancer pain is a multidimensional experience that frequently involves nociceptive, neuropathic, and mixed mechanisms operating simultaneously. The World Health Organization (WHO) analgesic ladder, first published in 1986, transformed cancer pain management by establishing a systematic, stepwise approach to analgesia. When properly applied, it provides adequate pain relief in 70-90% of patients.

Pain Mechanisms in Cancer

Nociceptive Pain

Somatic nociceptive pain arises when tumor infiltration, surgical trauma, or treatment-related injury activates nociceptors in skin, bone, muscle, and connective tissue. It tends to be well-localized with an aching or throbbing quality. Bone pain is the single most common type of cancer pain, most often resulting from metastatic disease originating in breast, prostate, or lung primaries. Metastases activate osteoclasts and trigger the release of inflammatory mediators including prostaglandins, endothelin, and nerve growth factor, ultimately causing periosteal distension.

Visceral nociceptive pain, by contrast, arises from tumor infiltration, distension, or compression of internal organs. It is poorly localized, deep, and cramping or pressure-like in quality, and often accompanied by referred pain patterns -- pancreatic cancer, for example, classically refers pain to the back.

Neuropathic Pain

Neuropathic cancer pain can be tumor-related or treatment-related. Tumors may directly invade or compress neural structures: a Pancoast tumor can produce brachial plexopathy, pelvic tumors can cause lumbosacral plexopathy, and base-of-skull metastases can produce cranial neuropathies. Treatment-related neuropathic pain includes chemotherapy-induced peripheral neuropathy (CIPN) from taxanes, platinum agents, vinca alkaloids, and bortezomib, as well as post-radiation plexopathy and post-surgical neuropathic syndromes such as post-mastectomy and post-thoracotomy pain. Neuropathic pain is characteristically burning, shooting, or electric shock-like, often accompanied by allodynia and hyperalgesia. It tends to be partially opioid-resistant and frequently requires adjuvant neuropathic agents for adequate control.

Mixed Pain Syndromes

Many cancer pain presentations involve simultaneous nociceptive and neuropathic components. A vertebral metastasis with epidural extension, for instance, produces both bone pain and radiculopathy. Recognizing the mixed mechanism is critical because it directly informs the selection of multimodal analgesic strategies.

<image>Medical illustration depicting the three major cancer pain mechanisms: a cross-section of vertebral bone metastasis showing tumor cells activating osteoclasts and releasing inflammatory mediators (nociceptive somatic), a pancreatic tumor compressing the celiac plexus and distending the pancreatic duct (nociceptive visceral), and a pelvic tumor infiltrating the lumbosacral plexus with demyelination and Wallerian degeneration (neuropathic), with each mechanism clearly labeled with characteristic pain descriptors</image>

Comprehensive Pain Assessment

Assessment Framework

A thorough cancer pain assessment begins with a detailed pain history covering location, quality, intensity (using a 0-10 numeric rating scale), temporal pattern, aggravating and alleviating factors, and response to prior treatments. Multidimensional tools add important information: the Brief Pain Inventory (BPI) quantifies how pain interferes with function, while the Edmonton Symptom Assessment System (ESAS) captures pain within the broader burden of cancer-related symptoms. Functional impact on activities of daily living, sleep, mood, and social participation should be documented.

Psychosocial screening is equally important. Depression (PHQ-9), anxiety (GAD-7), pain catastrophizing, existential distress, and spiritual concerns all modulate the pain experience and influence treatment response. Substance use history, including prior opioid exposure and risk assessment for aberrant behaviors (SOAPP-R), should be obtained -- though risk mitigation must never impede adequate cancer pain treatment. Finally, prognostic context matters: disease trajectory, goals of care, and estimated life expectancy all shape treatment planning.

Special Populations

Elderly patients require particular attention because altered pharmacokinetics and pharmacodynamics increase sensitivity to opioid side effects; the guiding principle is to start low and titrate slowly. Pediatric patients need age-appropriate pain assessment tools (FLACC for younger children, Wong-Baker FACES for older ones) and weight-based dosing. Cognitively impaired patients require behavioral pain assessment tools and input from family and caregivers, since self-report may be unreliable.

WHO Three-Step Analgesic Ladder

Original Framework (1986)

The WHO ladder provides a stepwise approach based on pain intensity. Step 1, for mild pain (NRS 1-3), calls for non-opioid analgesics such as acetaminophen and NSAIDs, with or without adjuvant medications. Step 2, for moderate pain (NRS 4-6), adds weak opioids like codeine or tramadol to the non-opioid and adjuvant foundation. Step 3, for severe pain (NRS 7-10), replaces weak opioids with strong opioids -- morphine, oxycodone, hydromorphone, fentanyl, or methadone -- while maintaining non-opioid analgesics and adjuvants.

Evolution and Modern Adaptations

Current practice has moved beyond rigid sequential escalation. The ladder is now applied bidirectionally, meaning patients presenting with severe pain should start directly at Step 3 without delay. Step 2 itself has become controversial: some guidelines, including those from the European Association for Palliative Care (EAPC), suggest bypassing weak opioids altogether and using low-dose strong opioids for moderate pain, given the ceiling effects and limited efficacy of agents like codeine and tramadol. A proposed fourth step adds interventional techniques -- nerve blocks, neuraxial analgesia, and intrathecal drug delivery -- for pain refractory to pharmacologic management.

Adjuvant medications are relevant at every step of the ladder. Corticosteroids such as dexamethasone address bone pain, cerebral edema, and visceral compression. Anticonvulsants (gabapentin, pregabalin) and antidepressants (duloxetine) target neuropathic components. Bisphosphonates and denosumab reduce skeletal-related events from bone metastases.

<image>Annotated diagram of the WHO analgesic ladder showing the three original steps with representative medications at each level, plus the proposed fourth step for interventional procedures, with bidirectional arrows indicating the modern approach of starting at any step based on pain severity, and a sidebar listing adjuvant medications (corticosteroids, anticonvulsants, antidepressants, bisphosphonates) applicable at all steps</image>

Breakthrough Pain Management

Breakthrough cancer pain (BTcP) is a transient exacerbation of pain that occurs spontaneously or in response to a specific trigger, despite otherwise adequately controlled background pain. It affects 40-80% of cancer patients with controlled baseline pain. The typical episode has a rapid onset (median 3-5 minutes to peak intensity), moderate-to-severe intensity, and short duration (median 30-60 minutes), with patients averaging 3-4 episodes per day. BTcP is classified as spontaneous (unpredictable), incident (triggered by identifiable precipitants like movement, weight-bearing, or coughing), or end-of-dose failure (pain returning before the next scheduled dose).

Treatment of BTcP

The standard rescue medication is an immediate-release opioid -- oral morphine IR or oxycodone IR -- dosed at 10-15% of the total daily opioid dose, with an onset of roughly 20-30 minutes. Rapid-onset fentanyl formulations (ROTFs) were designed to better match the rapid onset profile of BTcP. Available as transmucosal (OTFC/Actiq), buccal (Fentora), sublingual (Abstral), and intranasal (Lazanda) preparations, they achieve onset in 5-15 minutes. ROTFs must be titrated individually regardless of the background opioid dose, starting at the lowest available dose and escalating upward. They should never be used in opioid-naive patients. Non-pharmacologic strategies, including anticipatory dosing before known precipitants like dressing changes or physical therapy sessions, complement the pharmacologic approach.

Opioid Titration in Cancer Pain

Initiation

For opioid-naive patients, a reasonable starting regimen is oral morphine 5-10 mg every four hours (or an equianalgesic equivalent), with rescue doses of 10-15% of the total daily dose available every one to two hours as needed. Pain should be reassessed every 24-48 hours, with the scheduled dose increased by 25-50% for moderate pain or 50-100% for severe pain. Once daily requirements are established using short-acting agents, conversion to extended-release formulations provides convenience and more stable plasma levels.

Opioid Rotation

Opioid rotation -- switching from one opioid to another -- is indicated when a patient has inadequate analgesia despite dose escalation, intolerable side effects (neurotoxicity, excessive sedation, myoclonus), renal or hepatic dysfunction, or requires a change in route of administration. The technique involves calculating the equianalgesic dose using standardized conversion tables and then applying a 25-50% dose reduction to account for incomplete cross-tolerance, followed by titration to effect.

Methadone deserves special mention because of its unique pharmacology. It acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake in addition to its mu-opioid agonism. Its conversion ratios are complex and increase at higher morphine equivalent doses, making it a drug that requires an experienced prescriber and careful, unhurried titration.

Side Effect Management

Constipation is universal with chronic opioid use and requires a preventive bowel regimen (a stimulant laxative combined with an osmotic agent) initiated at the same time as the opioid. Peripherally acting mu-opioid receptor antagonists such as naloxegol and methylnaltrexone are available for refractory opioid-induced constipation. Nausea and vomiting affect 15-30% of patients initially but tolerance typically develops within 5-7 days; treatment options include metoclopramide, ondansetron, or haloperidol. Sedation is dose-related and warrants evaluation for concurrent sedating medications; persistent sedation may respond to psychostimulants like methylphenidate. Respiratory depression, often the most feared side effect, is actually rare in opioid-tolerant patients who are titrated appropriately -- pain itself serves as a physiologic antagonist to respiratory depression.

<image>Clinical flowchart for opioid titration in cancer pain, showing the process from initial assessment and opioid selection, through dose titration with reassessment intervals, decision points for breakthrough pain dosing, opioid rotation criteria, and side effect management protocols including bowel regimen, antiemetic therapy, and dose adjustment strategies, with color-coded pathways for mild, moderate, and severe pain</image>

Clinical Pearls

Cancer pain is always believed and always treated. Undertreatment of cancer pain is an ethical failure and remains the most common barrier to adequate symptom control. The WHO ladder remains a valid framework when applied bidirectionally; patients with severe pain should start at Step 3 without delay. Breakthrough cancer pain requires individually titrated rescue dosing, and rapid-onset fentanyl formulations should never be used in opioid-naive patients. Neuropathic components of cancer pain are common and often require adjuvant agents -- gabapentinoids, duloxetine, or tricyclic antidepressants -- in addition to opioids. Opioid rotation with an appropriate 25-50% dose reduction for incomplete cross-tolerance is a cornerstone skill. Regular reassessment using standardized tools such as the BPI and ESAS ensures treatment adequacy and identifies emerging complications before they become crises.

References

1. World Health Organization. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018.
2. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-e68.
3. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331-338.
4. Portenoy RK, Ahmed E. Cancer pain syndromes. Hematol Oncol Clin North Am. 2018;32(3):371-386.

Read this lecture as Markdown